Anneli Hällgren has been appointed the new head of preclinical development, including regulatory safety studies.
Hällgren has worked for the past ten years as a consultant in preclinical drug discovery and will now join the Aqilion team on a part-time basis.
“I’m convinced that Anneli Hällgren’s expertise will be extremely valuable for Aqilion’s continued preparations for clinical trials in the company’s phase-1-ready anti-inflammatory program Regulus, as well as the continued preclinical development in the Alnitak program. My colleagues and I are excited about the opportunity to work with Anneli and to benefit from her drive and experience in our operational team,” says Sarah Fredriksson, CEO of Aqilion.
Anneli Hällgren holds a PhD in physiology from Uppsala University, Sweden, and has more than 20 years of experience in research and development projects with a focus on a variety of indications and disease areas, including inflammatory and autoimmune conditions. Her career began at AstraZeneca, where she worked as a safety pharmacologist and preclinical project manager. Since then, she has held leading positions at companies such as KaroBio, Biolipox and Melacure Therapeutics.
Anneli has also belonged to the management of a major EU-funded platform project and has been involved in starting new biotech companies.
Photo Anneli Hällgren: Aqilion